Delving into the Latest Updates on Nantong Bencao Quadriga Medical Technology HK Limited with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Hemic and Lymphatic Diseases

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Biological products	1

Top 5 Target	Count

SLC7A5(L-type amino acid transporter 1)	1

This is a phase IIa, single-arm, open-label study to evaluate the efficacy and safety of NBQ72S, a novel amino acid conjugate drug targeting L-type amino acid transporter 1 (LAT1), in patients with breast cancer leptomeningeal metastases. All patients will receive study drug treatment every 28 days until withdrawal from treatment.

Start Date-

Sponsor / Collaborator

Parexel China Co.,Ltd.

[+3]

100 Clinical Results associated with Nantong Bencao Quadriga Medical Technology HK Limited

Login to view more data

0 Patents (Medical) associated with Nantong Bencao Quadriga Medical Technology HK Limited

Login to view more data

100 Deals associated with Nantong Bencao Quadriga Medical Technology HK Limited

Login to view more data

100 Translational Medicine associated with Nantong Bencao Quadriga Medical Technology HK Limited

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data